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Abstract 
Background 
Therapeutic vaccines are currently being optimized to enhance melanoma patients’ own immune 
defenses against cancer cells. The Melan-AMART-1 tumor antigen is frequently expressed in melanoma 
and has been widely used in clinical immunotherapy studies. We previously reported that vaccination 
with the native unmodified Melan-A (defined as EAA hereafter), but not the analog peptide (defined 
as ELA), despite its stronger binding to HLA-A2, elicited a polyfunctional phenotype (i.e. co-expressing 
genes associated with memory and effector attributes) by tumor-specific T cells, together with 
increased tumor cell killing capacities by these cells. 
Objective 
The present study aims at characterizing the timing of acquisition of memory/effector properties 
among individual tumor-reactive CD8 T cell clones in melanoma patients following vaccination with 
the native/EAA peptide, compared to responses induced with the analog/ELA peptide. Moreover, we 
assessed the evolution of the tumor-specific T cell clonotype repertoire across time following 
vaccination in both cohorts of patients and its specific selection at early time points as compared to 
the specific responses pre-existing before the start of immunotherapy.  
Methods 
We generated a large library of cDNAs (n = 1500) isolated from single Melan-A-specific effector-
memory (EM) CD28+ (memory-like; EM28+) and CD28- (effector-like; EM28-) T cells at different time 
points before and after peptide vaccination. Our highly sensitive single cell gene expression approach 
allowed the direct ex vivo characterization of individual tumor-specific T cells in melanoma patients 
who received either the native/EAA (n = 4) or the analog/ELA (n = 3) peptide vaccine. PCRs specific for 
the TCRβ-chain variable region were further performed to determine the TRBV/CDR3-based clonotype 
of each individual tumor-specific T cells across time after vaccination. 
Results 
When compared to pre-vaccine T cell phenotype, tumor-specific T cells underwent a drastic 
differentiation change into effector-memory following CpG vaccination, regardless of the type of 
peptide vaccine used (native/EAA or analog/ELA). Acquisition of the EM28+ phenotype shortly after 
vaccination was specifically associated with the significant increase in effector gene expression and 
concomitant reduction of a memory gene expression pattern (IL-7R CXCR3- CCR5-). Dominant 
tumor-specific TCR clonotypes were expanded during this process and many of them were maintained 
stable over time, as they also were found present at late time points after immunotherapy. Using the 
advantage of the single cell resolution, a difference in CD27 gene expression could be identified 
between EM T cells with dominant or non-dominant TCR clonotypes.  
Conclusions 
Melan-A peptide/CpG vaccination induced the strong T cell differentiation of tumor-reactive T 
cells, which was accompanied by increased effector gene expression and expansion of dominant 
clonotypes, in both native/EAA and analog/ELA based vaccine. Moreover, our data further suggest that 
tumor-specific T cells may undergo a maturation process during the course of vaccination, which may 
account for the differences observed in the co-expression of memory and effector genes within 
native/EAA EM28+ T cells at later time points. Finally, once established, the clonal composition of 
tumor-specific T cell responses was kept stable along immunotherapy. Collectively, such analyses 
provide important insights on the in vivo impact of natural over analog peptide vaccination on T cell 
polyfunctionality and clonotype selection induced by each type of vaccination. 
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Introduction 
Melanoma 
Melanoma is the deadliest type of skin cancer surpassing squamous and basal cell carcinoma 
despite their higher incidence. It is diagnosed in about 2’000 patients and accounts for nearly 500 
deaths each year in Switzerland (1). The main risk factor is the exposure to UV irradiation in 
predisposed individuals, which causes DNA damage and is reflected by the higher number of mutations 
found in melanomas relative to other cancer types (2). 
Melanoma derives from melanocytes, which contain melanin and gives the skin its pigmentation. 
Melanomas most frequently present as pigmented lesions of the skin or mucosae, but non-pigmented 
lesions may also be diagnosed (Fig. 1A-B). These amelanotic melanomas are a diagnostic challenge and 
tend to be diagnosed at more advanced stages (3). Importantly, melanomas may develop either from 
previous pigmented lesions such as naevi or normal skin (4). 
 
Figure 1. A. Melanoma subtypes. From left to right: superficial spreading melanoma, lentigo maligna 
melanoma, acral lentiginous melanoma and nodular melanoma (4) B. Amelanotic melanoma lesion (4) C. 15-year 
melanoma-specific survival curves according to stage of the disease at time of diagnosis (5). 
Evolution and prognosis 
Melanoma usually follows a progression pattern from the primary skin lesion to the lymphatic 
system and to distant organs. The prognosis of the disease is best apprehended using the Tumor-Node-
Metastasis (TNM) staging system (3). TNM stages with similar prognoses are usually pooled in four 
group stages (I-IV). Melanoma limited to the skin (stages I-II) may be classified into various subtypes 
with different local invasion patterns, either more parallel to the skin plane or with early vertical 
invasion (4). For all types, the most important prognostic feature is the thickness of the lesion, or 
Breslow index, which provides an indirect measurement of lymph node metastasis probability (6). The 
mitotic rate is the second most important independent prognostic factor in early lesions. Other 
parameters also carry prognostic value, such as ulceration and localization. 
Lymph nodes metastases (stage III) are a major negative prognostic factor as reflected by survival 
curves (Fig. 1C) and may often progress to stage IV with distant hematogenous metastases to the lungs, 
the bones, the brain and the liver (5,6). 
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Treatment 
Treatment options for melanoma patients include surgery, standard chemotherapy, targeted 
therapies and immunotherapy, while radiotherapy plays a more palliative role (7). Targeted therapies 
are recent developments and include mutated BRAF (vemurafenib, dabrafenib) and MEK inhibitors 
(cobimetinib, trametinib). They have shown improved progression-free and overall survival over 
standard chemotherapy, and may be combined for increased efficiency (8–11). However, long term 
progression-free survival could not be demonstrated with these targeted therapies. 
Melanoma immunotherapy is a rapidly evolving field. While it has long been limited to IL-2 and 
IFNα therapies, which were associated with major adverse effects (12), novel treatments like immune 
checkpoint inhibitors (CTLA4 and PD-1 inhibitors) and adoptive cell therapies are now available in the 
clinic (13). These treatments function through the stimulation of the anti-tumoral adaptive cellular 
immune response. Other immunotherapeutic modalities, such as peptide-based vaccines, the main 
subject of this report, are currently in development and aim at enhancing the same immune responses 
in a more targeted manner. 
Cytotoxic T cell immune response 
Cytotoxic CD8+ T cell are the primary effector of a potent anti-tumor immune response. The 
overarching goals of any immune-based therapy are to favor the activation of CTLs and promote their 
migration into the tumor bed. Although other cells types are directly implicated in the development of 
the immune response (CD4+ T cells, DC…), a large set of pre-clinical and clinical models have shown 
that cytotoxic CD8 T cells play a primary role in controlling and eliminating tumor cells (14,15). 
Functions 
Cytotoxic T lymphocytes (CTLs) are important components of the human adaptive immune 
system whose primary function is to destroy abnormal cells displaying specific antigens, such as viral 
epitopes or aberrantly expressed or mutated epitopes in the context of cancer. The target recognition 
relies on surface antigen presentation by the infected or malignant cells under the form of short 
peptides (9-10 amino-acids) loaded onto the major histocompatibility complex I (MHC-I). CTL 
specificity for a given antigen is ensured by direct interaction of their T cell receptor (TCR) and CD8 
coreceptor with the peptide·MHC-I complex. Upon antigen recognition, activated CTLs have the 
capacity to degranulate and to release cytotoxic proteins such as perforins, which form pores in the 
target cell membrane, and granzymes, which cleave and activate cytoplasmic caspases to induce the 
apoptotic cascade. CTLs may also produce chemokines (e.g.IFNγ, TNFα), which serve to activate other 
immune cells (e.g. macrophages), and promote antiviral pathways of somatic cells, such as MHC-I-
dependent antigen presentation. IFNγ also enhances MHC-II-dependent antigen presentation by 
macrophages to further stimulate the adaptive immune response. 
T cell receptor 
The TCR is a transmembrane heterodimer, composed of an α or γ subunit associated with a β or 
δ subunit, respectively. The majority of T cells express an α/β complex rather than a γ/δ complex. The 
TCR complex consists of the non-covalent association between the TCRαβ chains with the invariant 
CD3 proteins and the binding of the TCR to the pMHC complex triggers the activation of these CD3-
associated subunits allowing TCR-mediated signal transduction and T cell activation (16). 
In order to recognize a very large panel of possible foreign antigens, the adaptive immune system 
has the unique ability to generate a tremendous diversity of TCRs, allowing peripheral CTLs to express 
an extremely wide repertoire of TCRs. This diversity, known as gene-segment recombination, is 
ensured for each subunit by genomic recombination of one gene segment of the V (variable) group, 
which forms the 5’ of the coding sequence, with one gene segment of the D (diversity) group (in TCRβ 
and δ only) and one gene segment J (joining) group. These sequences code for the antigen recognition 
domain and are finally recombined with the constant 5’ part of the gene, coding for the rest of the 
extracellular domain and the membrane-spanning region. Recombination of the segments ensures a 
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large part of the TCR repertoire diversity in combination with other processes such as random 
nucleotide addition. 
T cell development and selection 
T cell precursors are produced by the hematopoietic system in the bone marrow. Their 
maturation is a multistep process, which mainly occurs in the thymus (17). During this process, 
thymocytes undergo TCR gene rearrangement as well as positive and negative selection, whereby the 
TCR affinity for self-antigens is the key element in determining the fate of T cells. Indeed, single positive 
CD4 or CD8 thymocytes expressing TCRs that efficiently interact with MHC-I or -II within a given affinity 
window will survive, exit the thymus and form the peripheral pool of mature CD8 and CD4 T 
lymphocytes. Importantly, the process of negative selection, which removes thymocytes that bind 
strongly to self-antigen/MHC complexes, is not perfect and allows T cells of relative high avidity for 
self-peptide/MHC to survive. While this selection step limits T cell autoimmunity and related disorders, 
it also restricts the anti-tumoral T cell response.  
CTL activation 
Peripheral mature CTLs that have not yet encountered any cognate antigen are called naïve (often 
defined as CD45RA+/CCR7+ or CD45RA+/CD62L+). These cells patrol the lymph nodes where they may 
become activated through antigen presentation, most commonly by dendritic cells, although other 
cells may also function as antigen-presenting cells (APCs) (e.g. macrophages and B cells). Antigen 
presentation alone is not sufficient to activate CTLs and will even induce anergy, a non-functional state 
which prevents further activation. Costimulatory molecules such as CD80/86 must be presented to the 
CD28 receptor present on naïve CTLs at the same time as the antigen to the TCR for proper activation 
and expansion (16). A third signal is necessary and is mediated by cytokines, such as IL-2. On the other 
hand, coinhibitory molecules may interfere with that process to promote immune tolerance and are 
expressed on either APCs or CTLs. A prototypic example is the CTLA-4 receptor which may compete for 
CD80/86 binding and negatively regulate activation (16). 
Dendritic cells 
Dendritic cells are present in virtually all tissues. Their main function is to phagocyte pathogens 
upon infection, and to migrate to the draining lymph node in order to present potential antigens to 
both CTLs and helper CD4 T cells through the corresponding MHCs. This complex multistep process is 
highly regulated to prevent activation in non-pathological situations. Dendritic cells must first receive 
adequate local signals in order to be properly activated. They may for example sense cytokines 
produced by tissue and immune cells. They also have the ability of directly recognizing invariant 
damage- and pathogen-associated molecular patterns (DAMPs and PAMPs) through a set of dedicated 
receptors. An important example of such receptors is the Toll-like receptor 9 (TLR9), which is sensitive 
to unmethylated CpG DNA sequences and may get activated upon corresponding microbial infection. 
Integration of these various types of signals is necessary to stimulate antigen presentation and allow 
the expression of costimulatory molecules at the surface of dendritic cells. Although this mechanism 
may be sufficient for CTL activation, an additional step is required to trigger a long-lasting and fully 
functional CTL response. This regulatory mechanism involves prior MHC-II-dependent antigen 
presentation to cognate activated CD4 T cells, which in turn license the dendritic cells through their 
CD40 receptor (18). Licensing is thought to rely on the enhancement of costimulatory molecules and 
the reduction of inhibitory molecule expression as well as induction of chemokines that may attract 
naïve CTLs through their CCR5 receptor (19). 
CTL expansion and differentiation 
Following acute antigen-specific stimulation, CD8+ T cells mainly differentiate into effector cells. 
These cells have full killing potential and migrate to the sites of infection to help clearing pathogen-
infected cells. They are, however, short-lived and will undergo apoptosis once the stimulus is removed. 
Another population of CTL is generated alongside and is characterized with a prolonged lifespan 
potential and varying degrees of self-renewal abilities. These cells are called memory cells as they have 
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the capacity to be reactivated and generate a faster effector response upon further encounter of the 
same antigenic stimulus, which constitutes the hallmark of an adaptive immune response (20). 
Expression of many genes have been associated with the memory phenotype and regulate the 
activation / proliferation potential (CD27, CD28, EOMES), cytokine response (CD127/IL-7Rα) and 
homing properties (CCR7, CXCR3, CCR5, CD62L) of these cells (21). 
Distinct subsets of memory cells have been described with varying degrees of memory and 
effector traits and may be distinguished by combinations of surface marker expression. Of the three 
main subsets, memory stem cells have the highest degree of self-renewal potential (22), followed by 
central memory cells (CD62LHi CD45RA- CCR7+) and effector memory (CD62LLo CD45RA- CCR7-) (23). 
Conversely, effector memory cells express higher levels of effector markers (IFNγ, PERF, GZMB, CD94) 
than central memory cells, which correlate with their higher cytotoxic potential. 
Effector memory (EM) cells may be further subdivided in CD28+ (EM28+) and CD28- (EM28-) cells 
(21,24). EM28+ cells express effector proteins at a lower level than EM28- cells, but may have increased 
memory and proliferation potential through the expression of memory genes and the telomerase 
enzyme, respectively. 
Cancer immunity 
The primary mechanism of cancer is the accumulation and selection of genetic anomalies leading 
to the loss of growth and proliferation regulation (2). These mutations lead to gene expression 
dysregulation, downregulating tumor suppressor genes while alleviating the repression of genes that 
are needed for cell survival and replication (oncogenes). These alterations may be recognized as 
foreign antigens by the adaptive immune system and serve as targets for immunotherapy. There are 
at least four classes of cancer antigens. In a decreasing order of specificity, neoantigens resulting from 
somatic mutations come first, followed by cancer testis antigens (a subset of genes that are normally 
not expressed in any tissue except male germ cells), differentiation antigens (genes expressed in the 
tissue from which the cancer arises, e.g. PSA in prostate cancer) and overexpression antigens (e.g. 
HER2 in breast cancer) (25). It is still not clear which specific antigens are or should be targeted in 
immunotherapy to achieve an efficient antitumoral response. Some hypotheses have been suggested, 
for example targeting neoantigens resulting from driver mutations may be more advantageous than 
targeting non-mutated self-antigens, since the T cell repertoire available for these antigens is not 
affected by central T cell tolerance (26). However, neoantigens also have the disadvantage of only 
being shared by a minority of patients with a given cancer type, while differentiation antigens are 
expected to be much more commonly expressed and shared among patients and tumor types. 
Cancer-immunity cycle 
An ideal anti-cancer CTL immune response based on antigens released by the tumor would rely 
on their efficient presentation by DCs for a proper priming / activation of CTLs. These CTLs would have 
the capacity to migrate back to the tumor and to specifically lyse cancer cells in an antigen-dependent 
manner. The killing of cancer cells would finally lead to the further release and presentation of cancer 
antigens leading to a virtuous cycle known as the cancer-immunity cycle (25). However, although 
spontaneous CTL responses against cancer antigens have been described, they usually do not provide 
protection against tumors (25). This poor anti-tumoral response may be due to many mechanisms 
including failure to recognize tumoral peptides as foreign antigens and evolution of the tumor to 
escape recognition by CTLs. Two well described examples of therapeutically exploited molecular 
mechanisms limiting the anti-tumoral immune response are the inhibitory CTLA4 receptor (cf. CTL 
activation) and the PD-L1/PD-1 system (27). The PD-1 receptor is a negative regulator expressed by 
activated CTLs. Its ligands, PD-L1/2, can be expressed and presented by tumor cells, thereby causing 
local immunosuppression within the tumor bed (27). Many other mechanisms have been described by 
which tumors may escape immune surveillance, in part by creating an immunosuppressive 
microenvironment through the secretion of specific cytokines/chemokines (e.g. CXCL12), and the 
recruitment of immunosuppressive cells, such as regulatory T cells, tumor-associated macrophages, 
myeloid suppressor cells and suppressive dendritic cells (28,29). Immunoediting is another important 
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concept and has been divided into 3 distinct phases defined as elimination, equilibrium and escape 
(30). During the elimination phase, the immune system recognizes and eliminates tumor cells. If only 
partial tumor elimination occurs, a temporary state of equilibrium may develop between the immune 
cells and the emerging tumor cells (31). With time, particular tumor clones evolve and acquire various 
capacities allowing such cells to resist and suppress the antitumor immune response, and leading to 
the escape phase. This model is supported by the observation that immunosuppressed patients are at 
increased risk of developing tumors, including these that are not of known viral etiology (32). In line 
with this theory, animal experiments have also shown that carcinogen-induced tumors from 
immunodeficient mice (Rag2-/-) are more immunogenic in syngeneic transplantation models than 
tumors from wild-type control mice (31). 
 
Figure 2. The cancer-immunity cycle is depicted as seven steps (25). Treatments and techniques aiming at 
enhancing the cycle are listed at the steps that they promote. 
Immunotherapy 
Immunotherapy aims at triggering de novo anticancer immune responses and/or at enhancing 
the cancer-immunity cycle (Fig. 2) and may be classified as passive and active immunization modalities. 
Passive immunotherapy 
By definition, passive immunotherapy protocols aim at enhancing the immune response by the 
exogenous administration of molecules with immunomodulatory properties, such as cytokines, 
antibodies, or of T lymphocytes (also defined as adoptive cell transfer). Administration of IL-2 and IFNα 
are among the first examples of immune modulators that have been used for the treatment of 
melanoma patients, allowing enhanced antigen presentation and CTL priming and activation (12,33). 
More recently, strategies of antibody-mediated blockade of CTLA4 and/or PD-1 have been developed 
and showed a significantly improvement of the clinical outcome of metastatic melanoma patients (34). 
For instance, Ipilimumab (anti-CTLA4) was shown to induce an increase in both progression-free and 
overall survival of advanced stage melanoma patients in randomized phase III trials (35). Nivolumab 
(anti-PD-1), is currently tested as a single agent in phase III trials (36,37). Moreover, a phase I study 
suggests that the combination of nivolumab and ipilimumab may further increase the treatment 
response rate with an acceptable safety profile (38). 
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Other more recent protocols include adoptive cell therapies where patients’ CTLs are collected 
and expanded in vitro before being reinfused (39). This simplistic summary hides many technical 
parameters that constitute as many hurdles (e.g. the need for immune depletion prior to reinfusion), 
as opportunities for further development of this technique (e.g. the possibility of T cell reprogramming 
to express modified TCRs or engineered chimeric antigen receptors). Many of these different protocols 
are currently in clinical trials (39). Of note, adoptive cell therapy was recently shown to induce durable 
remission (> 8 years) in a significant proportion of melanoma patients that had relapsed after multiple 
other treatments (40) and is currently being compared to ipilimumab in a phase III study 
(clinicaltrials.org ID: NCT02278887). 
Active immunotherapy 
Active cancer immunotherapy, or therapeutic vaccination, combines a multitude of protocols 
aiming at generating and/or boosting tumor-specific immune responses in vivo by the direct exposure 
to antigens. Active immunotherapy has been largely used in the clinic but the benefits of this approach 
have been, with rare exceptions, rather unsuccessful in generating potent tumor-reactive T cells 
allowing the control and destruction of tumor cells (41). A major hurdle is the appropriate and 
successful activation and expansion of those rare in vivo tumor-specific T cell precursors of low TCR 
avidity in order to mount a full protective anti-tumoral immune response. To achieve this ultimate 
objective, a variety of vaccine formulations (comprising both the antigen form and adjuvant 
composition) have been developed and were tested in clinical trials, including autologous antigen-
loaded dendritic cells, viral vectors, and proteins/peptides with chemical adjuvants (to stimulate native 
immune pathways) or in combination with helper peptides (to stimulate T helper-dependent cross-
presentation) (39,42). Different types of antigens have been used in these approaches from whole 
tumor cell lysates to short immunogenic peptides. Vaccination with defined proteins / peptides has 
the disadvantage of being restricted to specific HLA variants for antigenic presentation and might, 
therefore, be limited to subgroups of patients. It has, however, the theoretical advantage of directing 
the immunization to controlled specific targets, thereby limiting potential off-target effects. 
Sipuleucel-T (Provenge®) is a DC-based vaccine, which harbors the PAP antigen and is the first 
non-viral cancer vaccine approved by the FDA for asymptomatic and minimally symptomatic 
metastatic castration-resistant prostate cancer (39). Many other target-formulation pairs are currently 
being tested in the clinic, including some against melanoma. The most advanced melanoma target is 
gp100, a melanocyte differentiation marker, with a randomized phase III trial showing increased 
progression-free and overall survival after immunization with a gp100 peptide emulsified in Montanide 
ISA-51 (a water-in-oil emulsion) and IL-2 treatment vs. IL-2 alone (43). Other tumor-specific targets 
include cancer testis antigens, such as NY-ESO-1, and differentiation antigens, such as tyrosinase and 
Melan-A/MART1 (44), the latter being the subject of this study. Yet, further progress is required to 
improve the vaccines, with the goal to increase the strength of immune activation.  
Melan-A peptide vaccination study (LUD00-018 study) 
Design 
The LUD00-018 study (clinicaltrials.gov ID: NCT00112229) was an interventional phase I clinical 
trial, which aimed at determining whether vaccination with tumor antigenic peptides and both 
CpG7909 and Montanide adjuvants could induce a T-cell based immune response in stage III-IV 
melanoma patients (45). The design of the trial was built on the prior observation that co-
administration of the CpG7909 adjuvant (a single-stranded synthetic DNA composed of deoxycytidyl-
deoxyguanosin oligodeoxynucleotides known to trigger TLR9) to the Melan-A peptide and Incomplete 
Freund’s Adjuvant (IFA) vaccine formulation induced much higher Melan-A-specific CTL responses as 
compared to Melan-A and IFA as the only adjuvant . At that time, these results were obtained with the 
analog (ELAGIGILTV) HLA-A*0201-restricted Melan-A26-35 peptide, modified by an Ala to Leu 
substitution at position 27, allowing the enhanced generation of tumor-specific CD8 T cell responses 
(46,47). Thus, the clinical introduction of CpG7909 as adjuvant resulted in such a drastic increase in 
tumor-specific frequencies, raising the question whether immune CD8 T cell responses against the 
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natural (EAAGIGILTV) Melan-A26-35 peptide could as well be observed directly ex vivo and compared to 
the analog (ELA) T-cell mediated response. The LUD00-018 vaccine formulation was therefore based 
on the combination of both IFA and CpG7909 as adjuvants together with low doses of the natural 
(EAAGIGILTV) or analog (ELAGIGILTV) Melan-A peptide, either alone or in combination with the 
tyrosinase YMD peptide. 
The study included HLA-A2-positive adult volunteers with a histologically confirmed melanoma 
expressing Melan-A with or without tyrosinase. Patients with clinically significant heart disease, a 
history of immunodeficiency or autoimmune diseases, coagulation or bleeding disorders as well as 
patients that were unlikely to complete the study because of critical health conditions were excluded. 
The primary outcomes of the study were the immunological efficacy and the clinical safety during 
one year after the first vaccine dose vs. the pre-vaccine baseline. Efficacy was evaluated by the rates 
of tetramer-positive CTLs in peripheral blood and in vitro functional assays (Elispot IFNγ assays) (45). 
For patients with measurable tumor burden, the tumor response was monitored as a secondary 
outcome measure. 
Cytotoxic T lymphocyte response characterization 
One of the main interests of the LUD00-018-based study was to apply the novel CpG7909 vaccine 
formulation in melanoma patients and to directly compare vaccination with the natural (EAA) versus 
the analog (ELA) Melan-A peptide. CpG-mediated vaccination triggered a fast and strong tumor-
specific CTL response that was detectable directly ex vivo, readily after two rounds of vaccination, 
when using Melan-A-specific multimers combined to y flow cytometry as experimental read-out (Fig. 
3A). Moreover, compared with natural peptide vaccination, the analog peptide induced T cell 
frequencies that were approximately two-fold higher. Importantly, it is also the first synthetic vaccine 
formulation to consistently induce ex vivo detectable T cell responses even when using the natural 
tumor peptide antigen (45).  
 
Figure 3. A. Melan-A+ CD8+ T cell-specific frequencies before and after 2 or 4 natural/EAA (left panel) or 
analog/ELA (right panel) peptide vaccination doses. Of note, patient LAU444 showed high Melan-A-specific 
frequencies before vaccination due to a spontaneously primed tumor-specific CD8 T cell response (45). B. The 
killing potential of Melan-A+ CD8+ T cell clones isolated from patients vaccinated either with the natural (left 
panels) or the analog (right panels) peptide was measured in cytotoxic assays with T2-pulsed Melan-A peptide 
(natural versus analog) of increasing concentrations and were plotted as EC50 values for each indicated patient. 
This figure was adapted from (45). 
Another striking finding from this study (45) was that anti-tumoral CTL responses following 
natural peptide vaccination were of better quality, with superior tumor recognition, resulting in 
stronger protein expression of effector molecules (Granzyme B and Perforin), target cell killing, and 
cytokine production, as compared to vaccination with the analog peptide (Fig. 3B). 
Due to the strong immunogenicity induced by vaccination with peptide and the CpG adjuvant, 
this vaccine approach also provided the unique opportunity to study T cell-mediated priming and TCR 
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repertoire selection in humans. Most vaccinated patients showed progressive restrictions in the T cell 
clonotype diversity along cell differentiation (from EM28+ to EM28-) with preferential expansion of 
several co-dominant clonotypes of intermediate to high frequencies, irrespectively of whether the 
natural or the analog peptide was used for vaccination (48). In line with this study, we demonstrated 
that T cell repertoires generated against natural or analog Melan-A peptides following vaccination in 
melanoma patients exhibited slightly distinct, but otherwise overlapping and structurally conserved 
 TCR features (49). For instance, a strong preference of the TCR Vα2.1 segment usage and a 
conserved GLG motif within the CDR3 were observed in nearly all patients, regardless of the type of 
peptide (natural vs analog) vaccine.  
Together, these observations revealed that while tumor-specific T cell responses generated 
following vaccination with natural and analog tumor peptides exhibited similar T cell differentiation 
and TCR repertoire selection attributes (48,49), the natural peptide-induced T cells showed an 
enhanced overall functionality compared to the analog peptide (45,50). These data confirmed that 
vaccination trials using analog peptides require careful re-evaluation with regards to the risk of 
activating T cells with imprecise antigen specificity. 
We recently performed highly sensitive single cell gene expression profiling allowing the direct ex 
vivo characterization of individual tumor-specific T cells from melanoma patients with the aim to 
further investigate the observed functional differences between natural and analog Melan-A26-35 
peptide vaccination (51). Importantly, differential gene expression features could only be identified 
when tumor-specific T cell responses were carefully dissected at the memory (EM28+) and effector 
(EM28-) subpopulation level. While memory EM28+ T cells derived from patients receiving the analog 
ELA vaccine typically expressed genes associated to memory/homing function, natural peptide 
vaccination induced tumor-reactive EM28+ T cells with frequent co-expression of memory/homing- 
and effector-related genes. Surprisingly, the latter cells exhibited comparable levels of effector genes 
with those found in the differentiated EM28- tumor-specific cells or protective CMV-specific T cells 
(Fig. 4A). These gene expression differences nicely correlated with the enhanced killing potential of 
the EM28+ EAA-specific T cells in in vitro assays (Fig. 4B). These observations (51) revealed a previously 
unknown level of gene expression diversity, suggesting that such broad functional gene expression 
signatures within antigen-specific T cells may be critical for mounting efficient responses against 
pathogens or tumors. 
 
Figure 4. A. Effector gene expression rates in early- (EM28+) and late- (EM28-) differentiated cells in patients 
vaccinated with the natural (EAA) or the analog (ELA) peptide and in EBV and CMV-infected control subjects. B. 
Killing potential of Melan-A+ CD8+ T cell clones isolated from early- (EM28+) and late- (EM28-) differentiated cell 
populations from EAA versus ELA-vaccinated patients. Adapted from (51).  
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Project rationale and hypothesis 
The large majority of the results pertaining to the LUD00-018 clinical trial were obtained at 
relatively late time points after the start of vaccination (> 6 months). In the present study, we sought 
to assess whether the differences observed in the expression of effector mediators and cell 
functionality between memory EM28+ T cell following native and analog peptide vaccination were 
established early following the start of vaccination. To that end, we characterized and compared the 
expression of effector- and memory-related genes in single memory (EM28+) and effector (EM28-) 
tumor-specific CD8 T cells from seven patients receiving either the natural/EAA (n = 4) or the 
analog/ELA (n =3) peptide vaccine at early time points (< 3 months). Using this approach, we further 
addressed the question whether there was any discernible evolution in the expression of these gene 
expression signatures across time. 
Alongside the functional gene expression analysis, we aimed at characterizing the evolution of 
the tumor-reactive T cell clonotype repertoire across time. In particular, it remained unclear whether 
the peptide/CpG7909 vaccination allowed the preferential selection and expansion of Melan-A-
specific T cells that were already pre-existing before the start of immunotherapy (also defined as the 
spontaneously generated/tumor-induced vaccine-boosted model) or whether this vaccine formulation 
induced the selective activation and expansion of de novo rare tumor-specific T cell clones (defined as 
the vaccine-induced model). Moreover, both natural/EAA and analog/ELA peptide-vaccinated patients 
showed previously a high prevalence of relatively few co-dominant tumor-specific T cell clonotypes, 
which were mostly enriched in the differentiated EM28- subset, at later time points (48). We therefore 
asked whether this dominant T cell repertoire selection was established early after the start of 
vaccination and whether it occurred simultaneously in both cohorts (ELA vs EAA) of patients. For that 
purpose, we determined the clonotype of each individual tumor-specific T cell by sequencing the CDR3 
regions of TCRα and TCRβ mRNAs. 
Our overall goal was to identify gene expression signatures, which correlated with the increased 
T cell functionality and long-term persistence of particular tumor-reactive T cell clonotypes in 
melanoma patients following peptide vaccination. 
Aims 
Aim 1. Characterization of the effector and memory gene expression phenotype of Melan-A-
specific CTLs across time and at the single cell level 
a. Comparison of gene expression phenotype between native/EAA and analog/ELA peptide 
vaccinated patients  
b. Comparison of gene expression phenotype evolution across time after peptide vaccination 
c. Comparison of gene expression phenotype before and after peptide vaccination 
Aim 2. Characterization of the TCR clonotype repertoire across time and at the single cell level 
a. Analysis of TCR clonotype repertoire selection and evolution across time 
b. Comparison between vaccine-induced or tumor-primed/vaccine-boosted models of the 
Melan-A-specific CTL response 
c. Characterization of the gene expression phenotype of dominant tumor-specific T cell 
clonotypes 
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Material and methods  
Samples and CD8+ T cell sorting 
Ficoll-Hypaque (Pharmacia) centrifuged peripheral blood mononuclear cells (PBMC) samples that 
were originally drawn from each indicated patients at indicated time points before and after 
vaccination (Table 1) were cryopreserved in RPMI 1640, 40% FCS and 10% DMSO in the vapor phase 
of liquid nitrogen until further use. 
PBMCs were stained using the following combination: FITC anti-CD28 (BD Biosciences), HLA-
A*0201 analog/ELA Melan-A/MART-1-26-35 (A27L) multimers (TCMetrix Sàrl), ECD anti-CD45RA, APC 
A750 anti-CD3 and Krome Orange anti-CD16 (Beckman Coulter), and BV(421) anti-CCR7 (Biolegends), 
Alexa700 anti-CD8 (eBioscience) with Vivid Aqua (Life Technologies) for live cell discrimination. 
Samples were acquired and single cells sorted using a BD FACSAria cytometer (BD Biosciences) and the 
FACSDiva software (v.1.6, BD Biosciences). Photo Multiplier Tube (PMT) voltages were set using 
unstained PBMCs and compensations were calculated using single stained PBMCs. The following three 
tumor-specific CD8 T cell sub-populations were sorted as indicated (Table 1): the total Tetramer+ 
population with Vivid Aqua/CD16- CD3+ CD8+ Melan-A+ and the effector-memory (EM) CD28+/- 
subsets with Vivid Aqua/CD16- CD3+ CD8+ Melan-A+ CD45RA- CCR7- CD28+ (defined thereafter as 
EM28+ cells) and Vivid Aqua/CD16- CD3+ CD8+ Melan-A+ CD45RA- CCR7- CD28- (defined thereafter as 
EM28- cells).  
Peptide Patient Time point 
Days post- 
vaccination 
n (Tet+) n (CD28+) n (CD28-) 
Analyzed TCRα/β 
repertoire 
EAA LAU972 Early 45  80 34 TRBV1-3, 5*, 7, 13-
14, 16-17 94  59 31 
Late 374  39 39 
LAU1013 Early 101  80 37 TRBV1, 3, 7, 9, 13-
14, 17 Late 261  44 38 
LAU1015 Pre-vaccine -5 40   TRBV1, 3, 6-8, 13-
14, 16-17 Early 93  20 14 
Late 385  7 49 
LAU1106 Pre-vaccine 0 41   TRBV1, 3, 7, 13-14, 
17 Early 91  66 50 
Late 675  53 52 
ELA LAU444 Pre-vaccine -336  46 40 TRAV2 
TRBV1, 3, 7, 13-14, 
17 
Early 84  71 43 
Late 514  60 61 
LAU618 Late 430  43 36 TRBV3, 13, 17 
LAU1164 Pre-vaccine -7 17   TRBV1, 3, 7, 13-14, 
17 Early 38  57 41 
Late 241  20 22 
633   22 - 
Table 1. Number of analyzed cells (n) after quality controls (≥ 2 housekeeping gene expressed and ≤ 1 TCRα/β 
pair of genes detected per individual cell sample) according to patient, time points and sub-population. TRBV 
and TRAV genes whose expression was assayed are listed for each patient. Cells highlighted in green indicate 
that the corresponding data was previously generated by Gupta et al. (51).* Primers for TRBV5 expression were 
specific for TRBV5-1 subtypes. EAA, natural peptide; ELA, analog peptide.  
cDNA synthesis and amplification 
Single cells were sorted in each well of 96 well plates and directly lysed in 15 µl of oligo-dT primed 
reverse transcription mix (8 U MMLV-reverse transcriptase, 8 U RNAsin, 250 nM 20-mer-oligo-dT, 500 
µM dNTPs, 3 mM MgCl2, 33 mM µg/ml tRNA, 10 mM DTT, 80 mM KCl, 50 mM Tris-Cl pH 8.3, 1.25% 
Triton X-100). The cDNA was synthesized by incubation at 37 °C for 1 h and the enzymes inactivated 
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by incubating at 90 °C for 3 min. cDNA samples were stored at -80 °C. The cDNA was precipitated O/N 
at -80°C with 7.5 µl 7.5 M NH4Cl, 3 µl 10 µg/µl glycogen and 45 µl EtOH, pelleted 20 min at 13’000 rpm 
at 4 °C, washed with cold 70% EtOH, pelleted again and dried at room temperature. The cDNA was 
polyA-tailed in 5 µl terminal-deoxynucleotide-transferase reactions (2 U TdT, 500 µM dATP in 1x 
supplied buffer, Promega) for 30 min at 37 °C. The enzyme was inactivated for 3 min at 90 °C. 
The cDNA was amplified as described previously with 40 PCR cycles with the Iscove-dT primer (5’- 
CAT GTC GTC CAG GCC GCT CTG GGA CAA AAT ATG AAT TCT TTT TTT TTT TTT TTT TTT TTT T-3’) in the 
following final conditions: 5 U Taq polymerase, 200 nM Iscove-dT primer, 200 µM dNTPs, 2 mM MgCl2, 
0.1 µg/µl BSA, 50 mM KCl, 10 mM Tris-Cl pH 8.8, 0.5% Triton X-100. Reactions were denatured for 3 
min at 90 °C before enzyme addition and amplification with 5 initial cycles at low annealing 
temperature (50 s. at 94 °C, 2 min. at 37 °C, 9 min. at 72 °C) followed by 35 cycles at high annealing 
temperature (50 s. at 94 °C, 90 s. at 60 °C, 8 min. at 72 °C) and a final elongation step of 8 min. at 72 
°C. The amplified cDNA was stored at -80 °C. 
Target gene amplification, detection and sequencing 
Housekeeping, effector and memory genes were detected by PCR using previously published 
specific primer pairs (48,49,51). Briefly, 1 µl of amplified cDNA was used as template in 20 µl reactions 
(0.5 U KAPA HotStart Taq polymerase, 200 nM each primer, 200 µM dNTPs, 1.5 mM MgCl2, 0.1 µg/µl 
BSA, 50 mM KCl, 10 mM Tris-Cl pH 8.8). The enzyme was activated for 2 min at 94 °C and the targets 
were amplified with 40 cycles (30 s. at 94 °C, 45 s. at 58 or 60 °C as previously published, 60 s. at 72 °C) 
with a final elongation step of 10 min. PCR products were resolved on 2.5 agarose gels and scored with 
the help of a positive control using PBMC cDNA as template (0 = no specific product, 0.5 = minor 
specific product, 1 = major specific product). TCRα/β transcripts were detected with the same protocol 
with the following modifications: the forward primer concentration was increased to 300 nM and 
MgCl2 concentration was decreased to 1.25 mM. The final elongation step of the PCR was lengthened 
to 45 min at 72 °C. 5 µl of each PCR product was sent for sequencing (Fasteris) using the reverse Cα/β 
primer used for amplification to determine the sequence of the CDR3 region. 
Data analysis 
Effector / memory gene expression analyses 
Cells were considered as positive for a given gene when its expression score was equal to or 
greater than 0.5. Out of 1732 analyzed cells, 232 cells expressed less than two detectable 
housekeeping gene and thus were filtered out from all subsequent analyses. Moreover, 48 cells for 
which two TCRβ mRNAs were detected within one single sorted cell sample were also filtered out, 
leaving a total of 1452 cells that were included in further analyses. 
Cluster analysis of effector and memory genes was performed using the pooled data of all single 
cells from the early and late time points. Distance between each gene was calculated with a Pearson 
correlation coefficient. Dimension reductions were performed by aggregating the expression data of 
two genes. The aggregation variable was considered as positive for a given cell if one of the two genes 
was found expressed in that cell. 
The distribution bias (Δ) of two compared cell populations (A and B) in a given expression 
effector/memory gene expression pattern was defined as the difference of the ratios of number of 
cells (n) with the effector/memory marker combination to the total number of cells within each 
population: 
∆AB(effector/memory) =
𝑛A(effector/memory)
𝑛A
−
𝑛B(effector/memory)
𝑛B
 
Associated p values were calculated using the hypergeometric distribution and reflect the 
probability of observing number of cells with a defined effector/memory gene expression pattern in 
population A given the number of cells with the same expression pattern in the total population (A + 
B): 
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𝑃(𝑛A(effector/memory) | 𝑛A, 𝑛A∪B(effector/memory), 𝑛A∪𝐵) 
Clonotype repertoire analyses 
Clonotypes were considered for further analysis only when a positive TCRβ PCR amplification 
signal was observed and an interpretable TCR CDR3 sequence could be determined. TCRα chain PCRs 
were performed in a second step only in the single T cell samples of known and defined TCRβ CDR3 
sequences. 
Variable regions of TCRβ are referred to according to the nomenclature proposed by Arden and 
colleagues (52). Clonotypes that were found in more than two individual cell samples from the same 
patient were attributed a number, and are referred to by the following identification tag format: 
BV[TCRβ variable region number]-[clonotype number]. 
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Results 
For this study, we generated a large library of cDNAs (n = 1’732) isolated from individual tumor-
specific CD8 T cell subpopulations following vaccination of patients with either the natural (n = 4) or 
the analog (n = 3) Melan-A26-35 peptide vaccine together with IFA and CpG7909 (Table 1). For this 
purpose, we previously developed a strategy consisting of cell lysis and cDNA synthesis in a single-step 
procedure, followed by a modified PCR protocol that relies on the detection of specific cDNAs after 
global amplification of expressed mRNAs (51). Samples from melanoma patients (LUD00-018 study) 
were taken before vaccination (pre-vaccine), and at early (≤ 3 months) and late time points (> 6 
months) after vaccination, and were processed as described in the Material and methods section. For 
pre-vaccine time points, the Melan-A-specific T cells showed mostly a naïve-like phenotype (CCR7+ 
CD45RA+; data not shown) and total live single CD3+ CD8+ Melan-A+ T cells were directly sorted by 
FACS (defined as Tet+). After vaccination, the so-called effector memory cells (CD45RA- CCR7-) 
constituted the largest CTL population and were sorted into the following two subpopulations; early- 
(CD28+) and late-differentiated (CD28-) EM cells. The cDNA of each sorted cell was synthesized and 
amplified, and all generated single cell samples were tested for the expression of housekeeping genes 
(B2M, GAPDH and RPL13A). 1’500 cells passed the first quality control by expressing at least two 
detectable genes. Of these, 48 additional cells were excluded as two TRBV sequences were detected 
presumably because of contaminating cells during sorting, leaving 1452 cells that were included in the 
following analyses. The selected single cell samples were further subjected to specific effector-related 
(GZMB, CD94, IFNγ and PERF) and memory-related (IL-7Rα, CD27, CXCR3, CCR5 and EOMES) gene 
expression PCRs as described in the Material and methods section. 
The effector and memory gene expression data comprised nine binary variables that created a 
total of 512 possible gene expression combinations. To be able to detect statistically meaningful 
enrichments for each of these potential expression patterns, we sought to reduce the number of 
variables, in order to increase the number of single cells per bin. To that end, we performed a cluster 
analysis that comprised the effector- and memory-associated gene expression data of all patients and 
all populations across early and late time points to guide the dimensional reduction approach (Fig. 5A). 
Effector and memory genes segregated in two distinct clusters as expected given their known 
differential gene expression patterns found in EM28+ vs. EM28- cells (24; Fig. 6B & C). We selected 
three pairs of genes that showed the least distance from each other and aggregated their data into the 
following single variables; GZMB/CD94 (defined thereafter as GC), IL-7Rα/CD27 (defined as IC), and 
CXCR3/CCR5 (defined as CC). The aggregation variables were assigned the value of 1 if at least one of 
the two genes was expressed or 0 if none of them were expressed. The dimensional reduction strategy 
allowed us to limit the number of variables (including the gene expression paired groups) to a total of 
six, with three variables defining the effector gene-associated expression (IFNγ, GZMB/CD94 and PERF) 
and three variables defining the memory gene-related expression (IL-7R/CD27, CXCR3/CCR5 and 
EOMES). The number of potential gene expression combinations was thereby reduced to 64, increasing 
the average number of cells per bin to about 23, an acceptable number to detect biases in the gene 
expression distribution (data not shown).  
To test our analytical approach and the quality of our new set of single cell data, we first asked 
whether effector and memory gene expression differences could be observed between the well-
characterized EM28+ and EM28- tumor-reactive CD8 T cell subsets. For that purpose, we pooled all 
native/EAA and analog/ELA derived cell samples from post-vaccination time points and calculated the 
relative bias of distribution between cells of the two pooled groups (EM28+ vs EM28-) for each 
expression pattern bin and plotted the data as an heat map (Fig. 5B; left panel). The distribution biases 
of cells with the various effector or memory expression patterns were also plotted in the “total” row 
and column, respectively. The p values associated to the distribution biases of each bin were calculated 
using the hypergeometric distribution, and their absolute log10 values were signed according to the 
direction of the bias (+15% vs – 15%) and were plotted as a second heat map (Fig. 5B; right panel). 
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As expected, specific EM28+ CD8 T cells were overrepresented in bins with a high number of 
memory-associated genes (IL-7Rα/CD27+ with at least one other memory-associated gene; Fig. 5B). In 
sharp contrast, the EM28- tumor-specific CD8 T cells were mostly accumulated in GZMB/CD94+ bins 
with limited numbers of expressed memory-associated genes (Fig. 5B). Together, these results are in 
line with previous reports from our group (24,48), showing the high quality of our new set of data and 
validating the analytical approach used in this work. 
 
Figure 5. Comparison of effector and memory gene expression between early- and late-differentiated EM cells. 
A. Genes were sorted by cluster analysis according to their expression pattern. The results are displayed as a 
hierarchical clustering tree. The three groups of paired-genes whose expressions were aggregated to reduce the 
dimensions of the data are highlighted in green (GMZB/CD94 IL-R7a/CD27 and CXCR3/CCR5). Abbreviations are 
listed under each corresponding gene or paired-gene group. B. EM28+ (n = 699) and EM28- (n = 569) tumor-
specific CD8 T cell of all post-vaccine time points were distributed according to effector (columns) and memory 
(rows) gene expression patterns defined in panel A. Left panel: bias of CD28- vs. CD28+ populations relative to 
the total cell number of each group. Right panel: p values associated with the bias of CD28- vs. CD28+ distribution. 
GC: GZMB+ and/or CD94+; γ: IFNγ+; P: PERF+; IC: IL-7Rα+ and/or CD27+; CC: CXCR3+ and/or CCR5+; E: EOMES+.  
Aim 1a - Comparison of gene expression phenotype between native/EAA and 
analog/ELA peptide vaccinated patients  
We previously showed a significantly lower killing activity associated to a lower expression of 
effector genes in EM28+ tumor-specific CD8 T cells generated following analog (ELA) peptide 
vaccination compared to the equivalent native (EAA)-specific T cells showing enhanced co-expression 
of effector and memory-associated gene patterns (51). These results were based on samples acquired 
at relatively late time points (> 6 months) after the start of the vaccination. Moreover, at that time, we 
had only included two patients from each peptide vaccination cohort. Therefore, the work described 
here provides an extension of this study with the in-depth characterization of a total of four native/EAA 
and three analog/ELA peptide vaccinated patients at the single cell level. We first focused on the late 
time point and assessed whether this new complementary set of gene expression data from individual 
native/EAA and analog/ELA-specific CD8 T cell subsets at late time points correlated to our prior report 
(51). 
While no significant EM cell distribution bias among memory gene expression patterns could be 
observed between the native/EAA versus the analog/ELA peptide vaccinated cohort of patients (Fig. 
6A, lower left panel), EM28+ tumor-specific T cells isolated following EAA peptide vaccination 
accumulated in GZMB/CD94+ expression pattern bins as compared to the equivalent analog/ELA cells 
(Fig 6A, lower left panel). Consistently, cumulative gene expression of effector genes were significantly 
increased in the EM28+ T cells from native/EAA peptide vaccination cohort, in comparison to their ELA 
counterparts (Fig. 6B). 
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Figure 6. A. Comparison of effector and memory gene expression between native/EAA (Early CD28+ n = 305; 
Early CD28- n = 166; Late CD28+ n = 143; Late CD28- n = 178) and analog/ELA (Early CD28+ n = 128; Early CD28- 
n = 84; Late CD28+ n = 123; Late CD28- n = 141) peptide vaccination cohorts of patients EAA and ELA EM cell 
distribution according to effector (columns) and memory (rows) gene expression patterns in early/late and 
CD28+/- subsets. Left panels of each subset: bias of EAA vs. ELA populations relative to the total cell number of 
each group. Right panel: p values associated with the bias of EAA vs. ELA distribution. GC: GZMB+ or CD94+; γ: 
IFNγ+; P: PERF+; IC: IL-7Rα+ or CD27+; CC: CXCR3+ or CCR5+; E: EOMES+. B. Cumulative expression of effector 
genes according to the type of peptide vaccine (native/EAA vs analog/ELA), the time point (early vs. late) and the 
subpopulation (EM28+ vs EM28-). C. Cumulative expression of memory genes according to the type of peptide 
vaccine (native/EAA vs analog/ELA), the time point (early vs. late) and the subpopulation (EM28+ vs EM28-). B-
C. Associated p values were calculated with two-tailed paired t tests: * p < 0.05; ** p < 0.01. 
In contrast to these findings, only limited differences in the gene expression distribution between 
native and analog peptide-vaccinated patients were observed in the EM28- cells at late time points 
(Fig. 6A lower right panel). When we focused our analysis of the differential expression distribution 
between EAA and ELA patients at the early time points, effector EM28- cells showed also limited 
significant differences (Fig. 6A upper right panels, 6B-C). However, a small fraction of the analog/ELA 
EM28+ cells showed increased co-expression of effector and memory genes compared to the EAA 
counterpart single cells (Fig. 6 upper left panels), which could not be observed when cumulative gene 
expression histograms were used instead, since this approach separates the effector from the memory 
gene analysis (Fig. 6B-C). 
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Collectively, comparison of gene expression phenotype between the native and the analog 
peptide vaccine revealed only small cumulative gene expression (Fig. 6B-C) or gene expression 
distribution (Fig. 6A) differences in tumor-specific T cells from different subsets and at separated time 
points. The only exception was the strong enhanced expression of effector genes associated to 
memory gene co-expression observed within the native/EAA-specific EM28+ T cell subset at the late 
time point (Fig. 6A-C). Our new set of data therefore confirmed this previously observed phenotypic 
difference (51). 
Aim 1b - Comparison of gene expression phenotype evolution across time after peptide 
vaccination 
We next addressed the question whether the Melan-A-specific T cells could evolve phenotypically 
in terms of gene expression distribution during the course of peptide vaccination, by comparing early 
versus late time points. Since no major differences except for the EM28+ cells at the late time point 
were observed between single cell samples from native and analog peptide vaccine, we decided to 
pool all native and analog peptide vaccine derived samples and to consider only the effector versus 
memory gene expression data within EM28+ and EM28- subpopulations across time (Fig. 7). 
According to the effector/memory gene expression patterns, we observed an enrichment of 
effector gene signatures (GZMB/CD94+ IFNγ+) in EM28- T cells at the late time point, when compared 
to the early time point (Fig. 7A right panel). A similar trend was as well found within the EM28+ T cell 
subset. These gene expression changes were close to statistical significance when the evolution of 
these populations were considered patient by patient, but did not meet the 0.05 cutoff (p = 0.056; 
data not shown). The only obvious difference of EM28+ gene expression distribution was observed in 
the IL-7Rα/CD27+ CXCR3/CCR5- EOMES+ expression pattern, which showed a 2.44 fold enrichment at 
the late time point (p < 0.0001; Fig. 7A left panel). However, when we considered the contribution of 
each marker separately, CD27 and EOMES expression only slightly differed with time after vaccination 
(data not shown). Thus, excluding CD27 and EOMES from the analysis (and focusing on IL-7Rα+ CXCR3- 
CCR5- expression pattern) led to a 3.8-fold gene expression increase within EM28+ T cells from early 
to late time points (data not shown). 
Since these observations were based on pooled EM28+ cells from both native/EAA and 
analog/ELA samples at the studied time points, we next evaluated the expression of the IL-7Ra+CXCR3-
CCR5- pattern as well as each gene separately (IL-7Ra, CCR5 versus CXCR3) within the individual 
patients across time (Fig. 7B-E). All patients showed a statistically significant enrichment of the IL-7Ra+ 
CXCR3- CCR5- gene signature with time after vaccination (p <0.01; Fig. 7B). IL-7Rα expression 
contributed the most to this increase (p < 0.05; Fig. 7C), while differences in both CCR5 and CXCR3 
expression showed no statistically significant variations between early and late time points (Fig. 7D 
and E). 
In summary, Melan-A-specific EM T cells showed an evolution in both memory and effector gene 
expression phenotype over time. The change in memory gene expression was mostly found within 
EM28+ cells with IL-7Rα upregulation, while upregulation of effector gene expression was mostly 
observed in EM28- cells. 
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Figure 7. Comparison of effector and memory gene expression in tumor-specific T cell subsets between early 
(CD28+ n = 433; CD28- n = 250) and late (CD28+ n = 266; CD28- n = 319) time points. A. Distribution of EM cells 
at early vs. late time points according to effector (columns) and memory (rows) gene expression patterns in 
CD28+/- populations. Left panels of each subset: bias of cell distribution at late vs. early time points relative to 
the total cell number of each group. Right panel: p values associated with the bias of cell distribution at late vs. 
early time points. GC: GZMB+ or CD94+; γ: IFNγ+; P: PERF+; IC: IL-7Rα+ or CD27+; CC: CXCR3+ or CCR5+; E: 
EOMES+. B-E. Evolution of EM28+ cell populations with the indicated memory gene expression patterns. 
Expression levels of each indicated gene and gene combination (IL-7Rα+ CXCR3- CCR5-) were plotted according 
to patients (EAA: blue shades; ELA: red shades) and time points. Associated p values were calculated with two-
tailed unpaired t tests: * p < 0.05; ** p < 0.01. 
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Aim 1c - Comparison of effector and memory gene expression phenotype before and 
after peptide vaccination 
We next asked whether we could observe differences in effector and memory gene expression 
patterns between tumor-specific CD8 T cells isolated from pre-vaccine and early time points. Melan-
A-specific CTLs were rare at the pre-vaccine time point and the vast majority of them displayed a naïve-
like phenotype (CD45RA+ CCR7+ CD28+; data not shown). For these reasons, we sorted all Melan-A+ 
CTLs for further analysis (defined as Tet+ population). Patient LAU444 was an exception with the high 
spontaneous and pre-existing differentiated Melan-A-specific T cells, whereby both EM28+ and EM28- 
cells could be isolated before vaccination (Fig. 8A and 8B; Table 1; 53). 
 
 
 
Figure 8. Comparison of effector and memory gene expression in tumor-specific T cell subsets between pre-
vaccine and early time points+. A. Cumulative expression of effector genes to patients (LAU444 or all others) and 
time points (pre-vaccine vs. early) and the subpopulation (Tet+, EM28+ or EM28-). B. Cumulative expression of 
memory genes according to patients (LAU444 or all others) and time points (pre-vaccine vs. early) and the 
subpopulation (Tet+, EM28+ or EM28-). A-B. Associated p values were calculated with two-tailed paired t tests: 
* p < 0.05; ** p < 0.01. C. Average number of expressed effector genes in Tet+ or early-differentiated (CD28+) 
EM cells according to the type of peptide vaccine (EAA: blue shades; ELA: red shades) and each patient across 
time (pre-vaccine, early, late time points). Associated P values were calculated with two-tailed unpaired t tests: 
** P < 0.01. D. Distribution of EM cells at pre-vaccine vs. early time points according to effector (columns) and 
memory (rows) gene expression patterns. Tet+/CD28+ EM cells at pre-vaccine time points (n = 144) were 
compared with EM28+ cells at early time points (n = 433). Left panel: bias of cell distribution at early vs. pre-
vaccine time points relative to the total cell number of each group. Right panel: P values associated with the bias 
of cell distribution at early vs. pre-vaccine time points. GC: GZMB+ or CD94+; γ: IFNγ+; P: PERF+; IC: IL-7Rα+ or 
CD27+; CC: CXCR3+ or CCR5+; E: EOMES+. 
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In line with their naïve-like surface phenotype (CD45RA+ CCR7+), tumor-specific T cells expressed 
mostly memory/homing associated genes, with comparable cumulative levels to the EM28+ T cells 
following early time point vaccination (Fig. 8B). Given their naïve-like phenotype and previous reports 
(24), we expected that the Tet+ cells would also resemble to the “memory-like” EM28+ T cells in terms 
of reduced effector gene expression levels. While this was the case, the pre-vaccinated EM28+ T cells 
isolated from patient LAU444 also showed low expression levels of effector genes, which were similarly 
enhanced in early time point EM28+ T cells (Fig. 8A). Thus, Melan-A/CpG vaccination significantly 
triggered the expression of various effector genes within Melan-A-specific T cells, including patient 
LAU444. Similar results were obtained when the average total number of expressed effector genes 
was calculated for each individual patient (Fig. 8C). Overall this up-regulation in the average effector 
gene expression was highly significant (p < 0.01; Fig. 8C).  
We next investigated whether there was any significant effector/memory gene expression bias 
between the early time point EM28+ T cells and the Tet+ T cells isolated before vaccination using our 
dimensional reduction approach (Fig. 8D). As expected, pre-vaccine Tet+ were highly enriched in cells 
that did not express any effector-associated genes when compared to early time point EM28+. 
Interestingly, a significant fraction of these single cell samples also showed the preferential expression 
of the memory IL7-Rα/CD27+ CXCR3/CCR5- gene expression pattern (Fig. 8D; Fig. 7B). These biases 
were mirrored by a nearly symmetrical depletion in the IL-7Rα/CD27- CXCR3/CCR5+ gene expression 
signature. When the contribution of each gene marker was considered on its individual basis, IL-7Rα 
expression showed a 2.53-fold down-regulation between pre-vaccine and early post-vaccine T cells (p 
< 0.05; Fig. 7C), contrasting to the concomitant 3-fold-increase found for CCR5 (p < 0.01; Fig. 7D) and 
to a lesser extent for CXCR3 gene expression levels (p < 0.05; Fig. 7E) in EM28+ T cells at early time 
points.  
Together, these results show that peptide/CpG vaccination induced strong T cell differentiation 
of Melan-A-specific T cells, regardless of the type of peptide vaccine used (native/EAA or analog/ELA). 
Strikingly, the acquisition of the EM28+ T cell phenotype following vaccination was associated with the 
significant increase in effector gene expression concomitant to the reduced CD127/IL-7Ra memory 
gene levels. 
Aim 2a - Analysis of TCR clonotype repertoire selection and evolution across time 
The second main goal of this study was to characterize the TCR repertoire in the same individual 
cells whose effector and memory gene expression were characterized. We targeted our analysis 
toward specific TCRα/β families that we knew from previous studies to account for the majority of the 
dominant Melan-A-specific repertoire (48,49). Our method was based on PCR amplification using 
variable region-specific forward primers and reverse primers in their constant portions followed by 
sequencing of the CDR3 regions. Thereby, we systematically probed for TRBV1, 3, 7 13, 14 and 17 
transcripts in all newly included patient/time point. Additional TRBV families that were previously 
shown to play a prominent role in the Melan-A-specific repertoire of a minority of patients were also 
included as indicated in Table 1. 
We previously reported the progressive restriction in the TRBV/CDR3 diversity along cell 
differentiation from EM28+ to EM28-, with the preferential selection and expansion of few co-
dominant T cell clonotypes (48,51). This restriction in the EM28- T cell repertoire was not specific to 
Melan-A peptide vaccination as it could also be observed in chronic antiviral CTL immune responses 
(54,55). Such selected tumor- and virus-specific T cell clonotypes were called “dominant” if they 
accounted for more than 1% of the population. Here, we further asked whether the selection of such 
dominant clonotypes also occurred in our single cell database and whether the course of vaccination 
could influence this selection and expansion. The 1% cut-off was here not applicable given the 
relatively low number of cells with identified clonotypes and its frequency variation from one patient 
to another. We therefore decided to use an arbitrary absolute threshold of 3 cells to define a clonotype 
as dominant. These clonotypes and their proportion found within each EM28+ and EM28- subset are 
listed in Table 2 and are highlighted in Figure 9. 
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Figure 9. Clonotype repertoire analysis in EM28+ and EM28- T cell subsets in pre-vaccine, and early and late 
time points following peptide vaccination. Clonotype repertoire compositions are plotted as pie charts for each 
patient, subsets (Tet+, EM28+ or EM28-) and time points (pre-vaccine vs early vs late time points). Corresponding 
number of EM cells are indicated for each clonotype. Cells for which no TCRα/β transcript could be detected are 
depicted in light gray. Clonotypes that were detected only once in this study and were not previously detected 
in prior repertoire analyses of the same patients (48,49,51) were grouped together and depicted in dark gray. 
Dominant clonotype IDs are indicated in the color legends. 
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Consistent to these studies, the differentiated EM28- T cell subset was composed of several 
dominant clonotypes that were highly specific for each patient, and this TRBV/CDR3 preferential 
selection occurred in both type of peptide vaccine (native/EAA and analog/ELA) (Fig. 9; Table 2). Again, 
the proportion of dominant T cell clonotypes was globally reduced in the early-differentiated EM28+ 
T cell subset that was comprised of a more diverse TRBV repertoire, irrespective of whether native or 
analog peptide was used for vaccination. 
Strikingly, many of the most prevalent clonotypes were present at both early and late time points 
following vaccination (Fig. 9): Without including LAU444, which showed a vaccination-independent 
Melan-A-specific CTL response, 64 of the 122 cells with identified clonotypes at the early time point 
displayed 11 clonotypes that were also detected at the late time point. This indicates that once 
established the clonal composition of the tumor-specific T cell response is kept stable along 
immunotherapy. Yet, we also identified a few prevalent clonotypes either at early or at late time point 
(e.g. BV13-2 for LAU1015 and BV13-3 and BV14-1 for LAU444), suggesting some level of plasticity in 
the repertoire selection. 
Moreover, we calculated the prevalence of dominant T cell clonotypes within the total population 
of cells for each patient and type of peptide vaccine (ELA vs EAA), subset (EM28+ vs EM28-), and time 
point (early vs late) (Fig. 10A). As expected, differences were observed in the number of dominant 
clonotypes found between the less-differentiated EM28+ and the more-differentiated EM28- T cell 
subsets, with most patients displaying a higher proportion of dominant EM28- cells. However, this 
difference was only significant at the late time point (p < 0.05) since LAU1106 and LAU1015 presented 
an increased frequency of EM28+ dominant T cell clonotypes at the early time point (Fig. 10A). It 
remains unclear whether this result is due to (i) a smaller repertoire restriction at early time point, (ii) 
the relative low number of individual cells with identified clonotypes in EM28+ (n = 109) and EM28- (n 
= 144) T cells, biasing the statistical analysis or (iii) the low TRBV/CDR3 clonotype identification rate, 
making up between about 15% to 70% of total specific T cells and depending on patient, subset and 
time point. 
Previous TCR clonotyping (48,51) showed that 50 to 95% and 20 to 55% of EM28- and EM28+ 
tumor-specific T cells, respectively, had undergone preferential expansion. Thus, the rate of TCR 
TRBV/CDR3 clonotype identification was lower in our current study, and this was particularly true 
when we directly compared the data generated here to the previous one (i.e. EM28- T cells from 
LAU972 and LAU1013 at early versus late time point). Three main explanations may account for this 
discrepancy: (i) our TRBV targeted analysis ignored important TCRβ families that may possibly be 
present at early time point, (ii) the dominant clonotype frequencies were underestimated due to our 
new cut-off at 3% instead of 1%, and/or (iii) the sensitivity of our PCR-based technique was reduced. 
Consistent with the last argument, we were able to detect cells that had been previously tested 
negative for TRBV13 expression, when clonotypic PCRs were performed on the known TCR 
TRAV2/CDR3 clonotype sequence of BV13-1 clonotype of patient LAU444 (data not shown). 
Aim 2b - Comparison between vaccine-induced or tumor-primed/vaccine-boosted 
models of the Melan-A-specific CTL response  
We next asked whether the dominant tumor-specific T cell clonotypes that were found at early 
and late time points following peptide vaccination were already present before the start of 
immunotherapy. Except for patient LAU444, who presented a pre-existing tumor-primed and vaccine-
boosted dominant Melan-A-specific CD8 T cell clonotype defined as BVTR13-1/ELGTASY of high 
frequencies (53), we were unable to detect overlapping clonotypes between the pre-vaccine Tet+ cells 
and the early/ late time point EM cells (Fig. 9). The relatively low number of pre-vaccine cells (n = 184) 
combined to the relative reduced clonotype identification efficiency may in part explain this absence 
of common clonotype. An alternative explanation may come from the fact that pre-vaccine Melan-A-
specific T cells are mostly composed of naïve-like cells (Tet+) and display a higher clonal diversity, 
contrasting with the post-vaccinated specific cells undergoing drastic differentiation and clonotype 
selection (53 & unpublished observations). In such a scenario, one may not expect to find dominant 
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clonotypes, as those may be relative rare frequencies within the Melan-A-specific CD8 T cell 
compartment before vaccination. In line with this hypothesis, we could only identify the pre-vaccine 
dominant BV13-1/ELGTASY from patient LAU444, when focusing on the differentiated EM28- subset 
(Fig. 9).  
Aim 2c - Characterization of the gene expression phenotype of dominant tumor-specific 
T cell clonotypes 
In our previous studies, only little if any phenotypic difference could be observed between 
dominant and non-dominant tumor-specific T cell clonotypes, both in terms of effector or memory 
gene expression or target-specific killing (48). These conclusions were based on single ex vivo tumor-
specific CD8 T cells or on in vitro generated T cell clones derived from the late time point. We next 
asked whether our data confirmed these previous observations, and whether this was also the case at 
the early time point. Given the relative low clonotype identification rates, we first pooled the single 
cells from all patients and from both post-vaccination time points, only separating the EM28+ from the 
EM28- subpopulation and compared the memory and effector gene expression distribution within 
dominant vs. non-dominant clonotypes (Fig. 10B). 
Patient TRBV ID number CDR3 sequence TRBJ CD28+ CD28- 
LAU444 13 
 
1 CAS-SELGTASYEQ-YFG 2.7 1 46 
2 CAS-SSGQGNTGEL-FFG  2 1 
3 CAS-SYGQNQPQ-HFG  3 0 
14 1 CAS-SFGDNQPQ-HFG  5 0 
LAU618 3 1 CAS-SPPGLSGNIQ-YFG 2.4 12 0 
13 2 CAS-SPGTLADTQ-YFG 2.3 6 1 
4 CAS-SAGYGQPQ-HFG 1.5 0 4 
17 1 CAS-SPGALNTEA-FFG 1.1 1 21 
2 CAS-SIGPGLGQPQ-HFG 1.5 3 0 
LAU972 1 1 CAS-SVAHVDEQ-FFG 2.1 2 6 
2 1 CSA-SETGVGQPQ-HFG 1.5 3 1 
2 CSA-SQGLTEA-FFG 1.1 3 1 
3 CSA-REGGILTDTQ-YFG 2.3 3 0 
5 1 CAS-SLGQGDQPQ-HFG 1.5 4 12 
13 1 CAS-SETGGTEA-FFG 1.1 7 9 
6 CAS-SELGTASYEQ-YFG 2.7 3 0 
16 3 CAS-SQGGLGQPQ-HFG 1.5 3 0 
LAU1013 7 3 CAS-SQVMVGAVDGY-TFG 1.2 3 1 
5 CAS-ATAGQSNYGY-TFG  1 2 
13 1 CAS-SRDSALWISTDTQ-YFG 2.3 8 21 
3 CAS-SYSRDNEQ-FFG 2.1 4 3 
4 CAS-SYGGLGQPQ-HFG 1.5 3 0 
LAU1015 8 1 CAS-SLGDVDE-YFG 2.7 8 6 
13 2 CAS-SYLGMGQPQ-HFG 1.5 0 4 
LAU1106 3 1 CAS-SFQGLGQPQ-HFG 1.5 5 0 
2 CAS-RAPGLANNEQ-FFG 2.1 7 0 
5 CAS-SLGLAGNSEQ-FFG 2.1 4 0 
7 2 CAS-SQGDWGGSQPQ-HFG  5 1 
LAU1164 5 1 XXS-SQGITGGPQ-HFG 1.5 0 4 
Table 2. CDR3 sequences of dominant clonotypes by patient and TRBV gene. 
No significant difference could be observed in EM28+ cells (Fig. 10B, upper panels). Non-dominant 
EM28- T cells showed an enrichment in high memory gene expression patterns (IL-7Rα/CD27+ 
CXCR3/CCR5+), contrasting to the dominant EM28- T cells that accumulated low memory gene 
expression bins (IL-7Rα/CD27- CXCR3/CCR5-; Fig. 10B, lower panels). Small accumulation biases were 
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also observed among effector gene expression patterns, but were of little significance as revealed by 
the associated P values. 
 
Figure 10. Comparison of effector and memory gene expression between late-differentiated (CD28-) EM cells 
with dominant vs. non-dominant clonotypes. A. The cumulative prevalence of dominant clonotypes of each 
patient was plotted as stack histograms across time in EM28+ and EM28- cells. The prevalence was calculated 
relatively to the total number of cells with identified clonotypes. Associated p values were calculated with two-
tailed paired t tests: * p < 0.05. B. Distribution of early- and late-differentiated EM cells with dominant (CD28+ n 
= 107; CD28- n = 130) vs. non-dominant (CD28+ n = 162; CD28- n = 56) clonotypes according to effector (columns) 
and memory (rows) gene expression patterns. Data of pre-vaccine time points and cells with undetermined 
clonotypes were excluded from the analysis. Left panels of each subset: distribution bias of cells from indicated 
compared groups relative to the total cell number of each group. Right panels of each subset: p values associated 
with the distribution bias of cells from indicated compared groups. GC: GZMB+ or CD94+; γ: IFNγ+; P: PERF+; IC: 
IL-7Rα+ or CD27+; CC: CXCR3+ or CCR5+; E: EOMES+. C-D. The cumulative prevalence of indicated memory gene 
expression patterns of all patients was plotted as stack histograms according to EM cell population (CD28+/-) 
and clonotype (dominant/non-dominant). Associated p values were calculated with two-tailed paired t tests: * p 
< 0.05. 
Since the number of EM28- cells with identified clonotypes varied greatly from one patient to 
another, and, with it, their relative contribution to this pooled analysis, we also addressed whether 
these biases were observable at early and/or late time point by calculating the total rates of memory 
gene expression for each subpopulation separately (Fig. 10C). The prevalence of IL-7Rα/CD27+ 
CXCR3/CCR5+ was significantly reduced in EM28- cells with dominant clonotypes relatively to their 
non-dominant counterparts (p < 0.05; Fig. 10C). This difference was mainly due to the significant CD27 
downregulation in dominant EM28- cells (p < 0.05; Fig. 10D). These results are interesting but should 
be interpreted with caution given the low number of cells included in these analyses.  
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Discussion 
The first main aim of our study was to describe the effector and memory phenotype of Melan-A-
specific CTLs at the single cell level over time and in both arms of the LUD00-0018 study. As previously 
described (51), EM28+ cells of EAA patients showed a higher effector gene expression at the late time 
point compared to similar cells from ELA patients, confirming the quality of our new set of data (Fig. 
5C). Moreover, our results revealed a phenotypic evolution of the Melan-A-specific CTLs upon 
vaccination and between early and late time points after vaccination. Notably, these changes consisted 
of an upregulation of all effector gene expression upon vaccination. Using a novel data analysis 
approach, we were also able to identify a memory gene expression pattern (IL-7Rα+ CXCR3- CCR5-), 
which was downregulated upon vaccination and became upregulated again at later time points.  
The second aim of our study was to characterize the TCR repertoire of Melan-A-specific CTLs 
across time. Our analyses show that Melan-A vaccination stimulated the expansion of previously 
undetectable clonotypes, which, for the most part, subsequently show persistence over time. We also 
confirmed that the repertoire of EM28- cells was restricted to fewer more prevalent clonotypes 
compared to their EM28+ counterpart. Focusing on the dominant clonotypes, we were able for the 
first time to identify differences in memory gene expression between these and non-dominant control 
clonotypes. 
Effector and memory phenotype evolution upon vaccination 
By comparing Melan-A-specific CTLs isolated from pre-vaccine and early post-vaccine time points, 
we were able to observe two main differences. First, all tested effector genes were found to be 
upregulated upon vaccination and remained high at the late time point (Fig. 8A & C). This effect was 
observed in all analyzed patients (Fig. 8C). For three patients, the pre-vaccine prevalence of Melan-A-
specific CTLs was low and all of these cells had to be sorted for analysis regardless of their phenotype 
(e.g. naïve, EM28+, EM28-). This bias could partially explain the difference in gene expression. 
However, the same difference was observed in the fourth patient, LAU444, from which both EM28+ 
and EM28- cells could be isolated before vaccination as this patient had developed a spontaneous 
Melan-A-specific CTL response (Fig. 8A & C). Hence, we can conclude that our vaccination protocol is 
able to boost effector gene expression even in the case of a previously established Melan-A-specific 
response. Second, we were able to distinguish a memory gene expression pattern (IL-7Rα+ CXCR3- 
CCR5-), which was concomitantly downregulated at early time point post vaccination. This analysis 
may suffer from the same bias as mentioned above for the effector gene regulation. Yet again, LAU444 
showed a similar regulation pattern of these memory gene transcripts (although to a lesser degree for 
CXCR3), suggesting that they were indeed influenced by the vaccine and not only by a spontaneously 
generated/tumor-induced stimulation and differentiation of the tumor-specific CD8 T cells. 
Interestingly, when we compared the EM28+ cells from the late and early time points, the same 
memory, IL-7Ra+ CXCR3- CCR5-, gene expression pattern was upregulated again over time after 
vaccination, (Fig. 7A-B). This difference was shared by all patients except one and constituted one of 
the most obvious changes that we could detect for either EM28+ or EM28- cells between the two time 
points. Among the three genes involved, IL-7Rα was the only one showing significant regulation on its 
own. These data are consistent with IL-7Rα protein expression assays performed by FACS in our lab, 
which showed an initial decrease in IL-7Rα expression in all patients upon vaccination and a slighter 
re-upregulation over time, especially in EAA patients (Gannon et al. Manuscript in preparation). 
 The significance of the regulation of these memory genes is not clear. The genes that we 
monitored, which are commonly labeled as “memory-associated” genes, actually have heterogeneous 
functions. IL-7Rα is a specific subunit of the receptor sensing IL-7, which functions to enhance CTL 
survival and proliferation. The fact that it became upregulated again upon continuous vaccination is 
interesting as it could be the marker of a longer lasting memory response to the target antigen. 
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Overall the data regarding EM cell differentiations showed that our vaccination protocol not only 
induced higher frequencies of Melan-A-specific CTLs but also had an effect on their phenotype and 
might thereby increase their effector function and their survival.  
Repertoire analysis 
Our repertoire analysis yielded interesting results. We were able to observe the persistence of a 
majority of clonotypes through the early and late time points (Fig. 9). These results showed that 
vaccination was able to induce early on a Melan-A-specific repertoire that could remarkably persist 
over time. On the other hand, short of half the clonotypes observed at one time point were not 
detected at the other, thereby revealing that some repertoire plasticity was still possible after three 
months of repeated vaccine doses. The highest degree of repertoire stability was actually observed in 
the spontaneous Melan-A-specific response of LAU444, where the dominance of the BV13-1 clonotype 
over the EM28- cell repertoire remained virtually intact from nearly one year before the start of 
vaccination to more than a year and a half after (Fig. 9). This observation suggested that the repertoire 
became physiologically more difficult to alter after it had reached a steady state for a long time. 
The relative stability of the repertoire after vaccination strongly contrasted with the fact that no 
common clonotype could be found between pre-vaccine Tet+ and early time point EM28+ cells in 
patients other than LAU444 (Fig. 9). This is interesting as it suggested that the vaccination stimulated 
relatively rare clones among the Melan-A-specific CTL population at the beginning. 
Using the advantage of the single cell resolution of our analysis to its fullest, we were able to 
distinguish a downregulation in CD27 expression between EM cells with dominant clonotypes. This 
difference was mainly observed, and was only significant, in EM28- cells, which displayed a higher 
prevalence of dominant clonotypes and a lesser level of CD27 transcript (Fig. 10A & D). The significance 
of this differential expression was not clear. CD27 is a marker of lesser differentiation and its 
downregulation could be linked to the enhanced proliferation necessary for a CTL clone to achieve 
dominance. 
Data quality, strengths and limitations 
Our data nicely reproduced previously observed differences, such as the lower memory gene 
expression and repertoire restriction to fewer and more prevalent clonotypes in EM28- cells compared 
to their EM28+ counterparts (Fig. 5B & 6C), as well as the higher effector gene expression of EM28+ 
cells from EAA patients compared to ELA-derived controls. These observations were as many indicators 
of the quality of our data set. 
The main strength of the present study lies in its very high resolution and dimensionality. These 
characteristics allowed us to identify specific gene expression patterns that were regulated over time 
(e.g. IL-7Rα+ CXCR3+ CCR5+; Fig. 7A-E) or in specific subpopulations. A nice example of the power of 
this approach is shown in Fig. 10C-D: simultaneously determining the clonotype of each single cell as 
well as its gene expression phenotype enabled us to cross these data and allowed the identification of 
gene expression differences among cells with dominant or non-dominant clonotypes. 
Nonetheless, there remains some technical limitation to this study. The cDNA amplification 
method that we used is a multistep process that must be performed on each single cell separately. 
Each target gene must also be amplified separately, which again increased the number of tubes / plates 
to handle. These disadvantages hindered the throughput, and thereby limited the total number of cells 
and the number of patients that might be analyzed. Also, as the generated gene expression data of 
binary nature, a relatively high number of cells were required in order to get meaningful data from this 
stochastic output. These limitations were especially sensible in analyses focusing on smaller subsets of 
cells. For example, the number of cells with dominant clonotypes (Fig. 10B) precluded a more detailed 
analysis of their phenotype over time as splitting the cells between the two time points would have 
reduced their number too much. Another example is the number of cells with identified TCR clonotype 
at the pre-vaccine time points. Our study was not designed to detect rare clonotypes to begin with and 
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a much higher number of cells would presumably be necessary to detect common clonotypes between 
the pre-vaccine cells and the later time points. 
Technical improvements are therefore needed to enhance the throughput, quality and sensitivity 
of such large scale analyses. If we were to imagine an ideal technique for the characterization of the 
CTL immune response at the single cell, the capacity to process massive numbers of samples in parallel 
and the simultaneous quantitative measurement of gene expression and TCR gene sequencing would 
probably be its foremost features. 
Recently, various methods have been published, describing single cell cDNA high throughput 
sequencing (48,56–58). These RNA-Seq methods virtually enable to read the whole transcriptome of 
any given cell. In addition, high-throughput sequencing techniques may be adapted to analyze a large 
number of samples in parallel. This is made possible by genetic barcoding of sequencing libraries, which 
allows many samples to be pooled and sequenced together. Sequences may be deconvoluted at the 
data analysis stage and reattributed to each sample by the simultaneous sequencing of the barcodes. 
The first single cell RNA-Seq approach to have been described is very similar to our cDNA amplification 
protocol. It is based on the combination of poly-dA tailing of the cDNA followed by PCR amplification 
using oligo-dT containing primers (57). However, this method precludes the introduction of barcodes 
in the first steps of the library synthesis and would therefore require a separate sample processing. 
Two other methods were published more recently and are compatible with genetic barcoding at a step 
as early as reverse transcription (56,58). 
Target enrichment is a method to reduce the diversity of a library to focus on sequences of 
interest. A large scale example is exome sequencing which is most often performed by in solution 
hybridization (59). Lower throughput PCR-based techniques have also been described (59). Targeted 
sequencing enables a further increase in number of samples that may be processed in parallel while 
retaining a high number of reads per target sequence. Such a strategy would be required to process 
relatively high number of samples (e.g. > 1’000 single cells as in the present study). It has indeed been 
applied recently to single CD8+ T cells and involved target-specific reverse transcription and multiplex 
nested PCRs to amplify the target cDNAs (60). This method was successfully applied to assay for the 
expression of more than a hundred genes in parallel including the TCRα/β CDR3 sequences. The main 
drawback of this technique is that the gene targeting was not dissociable from library synthesis, which 
precludes the analysis of other genes expression from the same starting material. Also, sample 
barcoding could only be performed in the final steps of library generation, implying that earlier 
amplification steps have to be done in separate reactions for each cell, thus reducing the throughput 
and the reproducibility of the data. To our knowledge, no ideal technique has been described yet, but 
combinations of allowing sample barcoding at the level of reverse transcription and orthogonal target 
selection approaches seem like an interesting potential answer to the single cell analytical challenge. 
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